- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07612137
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBI3005 Combination Therapy in Participants With Advanced Solid Tumors
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Yang Luo
- Telefonnummer: +86 21 3183 7200
- E-post: yang.luo@innoventbio.com
Studera Kontakt Backup
- Namn: Yulong Zhang
- Telefonnummer: +86 21 3183 7200
- E-post: yulong.zhang@innoventbio.com
Studieorter
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- SunYat-Sen University Cancer Center
-
Kontakt:
- Li Zhang
- Telefonnummer: 020-87343458
- E-post: zhangli@sysucc.org.cn
-
Kontakt:
- Wenfeng Fang
- Telefonnummer: 020-87343458
- E-post: fangwenfeng@sysucc.org.cn
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Has signed a written informed consent form (ICF) and is able to comply with the scheduled study visits and related procedures.
- Age ≥ 18 years, irrespective of gender.
- Confirmed diagnosis of locally advanced unresectable or metastatic solid tumor.
- Expected survival ≥ 12 weeks.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.
- Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days prior to the first study drug administration.
- Adequate bone marrow and organ function.
Additional Inclusion Criteria for Cohort 1:
- Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
- Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
- In the safety run-in phase, NSCLC participants who have received prior standard therapy.
- In the cohort expansion phase, participants without driver gene mutations who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease.
Additional Inclusion Criteria for Cohort 2:
- Histologically or cytologically confirmed unresectable locally advanced or metastatic non-squamous NSCLC.
In the safety run-in phase, participants should have received prior standard therapy.
In the cohort expansion phase:
- Cohort 2A: NSCLC participants without driver gene mutations (including at least EGFR, ALK, and ROS1, with written documentation) who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.
- Cohort 2B: NSCLC participants with tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens, who have experienced disease progression after prior EGFR-TKI therapy.
Additional Inclusion Criteria for Cohort 3
- Histologically or cytologically confirmed unresectable locally advanced or metastatic NSCLC.
- Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology specimens.
- In the safety run-in phase, participants should have experienced disease progression after prior EGFR-TKI therapy.
- In the cohort expansion phase, NSCLC participants who have not received prior systemic anti-tumor therapy for unresectable locally advanced or metastatic disease. Participants who received neoadjuvant/adjuvant therapy are eligible if disease recurrence or progression occurred >6 months after the last neoadjuvant/adjuvant therapy.
Exclusion Criteria:
- Participation in any other interventional clinical study, except for observational (non-interventional) studies or the follow-up period after the end of study treatment in an interventional study.
- Prior treatment with antibody-drug conjugate (ADC) drugs bearing a camptothecin or its derivative (topoisomerase I inhibitor) small-molecule payload.
- Prior to the first dose of study drug: a) Within 4 weeks: Received intravenous chemotherapy, macromolecular targeted therapy, antibody-drug conjugates, immunotherapy, endocrine therapy, cell therapy, intraperitoneal perfusion chemotherapy, tumor embolization, or interventional chemotherapy. b) Within 2 weeks or 5 half-lives (whichever is shorter): Received oral chemotherapy, small-molecule targeted therapy, or traditional Chinese herbal medicines indicated for anti-tumor treatment. c) Within 4 weeks: Received radical radiotherapy; within 2 weeks: Received palliative radiotherapy. d) Within 2 weeks or 5 half-lives (whichever is shorter): Received strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4). e) Within 4 weeks: Underwent major surgery (craniotomy, thoracotomy, laparotomy, or other surgeries deemed ""major"" by the investigator, excluding puncture biopsy), or has severe unhealed wounds, trauma, or ulcers; within 2 weeks: Underwent laparoscopic exploratory surgery. f) Within 4 weeks: Received live vaccine (mRNA and non-replicating adenovirus vaccines are not considered live vaccines).
- Presence of adverse events from prior anti-tumor therapy that have not resolved to Grade 0 or 1 per NCI-CTCAE v5.0 [excluding Grade 2 alopecia, fatigue, pigmentation, insomnia, peripheral neuropathy, hypomagnesemia, and toxicities stably controlled by medication (e.g., hypothyroidism stably controlled by replacement therapy, hypertension with blood pressure stably controlled below 160/100 mmHg by antihypertensive medication)].
Additional Exclusion Criteria for Cohort 1:
- History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
- History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.
Additional Exclusion Criteria for Cohort 2:
- History of active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to the first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy.
- History of significant toxicity associated with immune checkpoint inhibitor administration that required permanent discontinuation of such therapy.
- History of hemoptysis within 3 months prior to the first dose (blood volume >2.5 mL per cough or cumulative daily hemoptysis >10 mL), or current active bleeding.
Continuous use of aspirin (>325 mg/day) or other non-steroidal anti-inflammatory drugs known to inhibit platelet function within 2 weeks prior to the first dose."
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Cohort 1:IBI3005+Sintilimab+ Carboplatin+IBI305
|
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Anti-PD-1 Monoclonal Antibody
Recombinant humanized anti-VEGF monoclonal antibody
Second-generation platinum-based chemotherapy drugs
|
|
Experimentell: Cohort 2:IBI3005+Sintilimab+ Carboplatin
|
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Anti-PD-1 Monoclonal Antibody
Second-generation platinum-based chemotherapy drugs
|
|
Experimentell: Cohort 3:IBI3005+Limertinib/Osimertinib
|
Bispecifikt monoklonalt antikropp-camptothecinderivatkonjugat för injektion (Fo-kod: IBI3005)
Third-generation EGFR-TKI
Third-generation EGFR-TKI
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
total överlevnad (OS)
Tidsram: Upp till 3 år
|
Upp till 3 år
|
|
|
Antal försökspersoner med kliniskt signifikanta förändringar i resultat av fysisk undersökning
Tidsram: Upp till 3 år
|
Kliniskt signifikanta onormala fysiska undersökningsfynd rapporterade av utredaren.
|
Upp till 3 år
|
|
Antal försökspersoner med kliniskt signifikanta förändringar i vitala tecken
Tidsram: Upp till 3 år
|
Vitala tecken inklusive kroppstemperatur, puls, andningsfrekvens, SpO2 och blodtryck
|
Upp till 3 år
|
|
progressionsfri överlevnad (PFS)
Tidsram: Upp till 3 år
|
utvärderat enligt RECIST v1.1-kriterierna.
|
Upp till 3 år
|
|
Number of subjects with adverse events
Tidsram: Up to 3 years
|
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
|
Up to 3 years
|
|
Number of subjects with treatment emergent adverse events
Tidsram: Up to 3 weeks
|
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
|
Up to 3 weeks
|
|
Number of subjects with adverse events of special interest
Tidsram: Up to 3 years
|
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
|
Up to 3 years
|
|
Number of subjects with serious adverse events
Tidsram: Up to 3 years
|
defined as any untoward medical occurrence, whether or not thereis a causal relationship with the study drug, in a clinical study subject from the time informed consent form is signed
|
Up to 3 years
|
|
Dose limiting toxicities (DLTs)
Tidsram: Up to 3 weeks
|
Dose limiting toxicities (DLTs) to establish MTD and/or RP2D.
|
Up to 3 weeks
|
|
Number of subjects with clinically significant changes in laboratory tests results
Tidsram: Up to 3 years
|
Clinically significant abnormal laboratory tests results reported by the investigator.
|
Up to 3 years
|
|
Objective Response Rate, (ORR)
Tidsram: Up to 3 years
|
as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
duration of response (DCR)
Tidsram: Up to 3 years
|
as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
time to response (TTR)
Tidsram: Up to 3 years
|
as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
|
duration of response (DoR)
Tidsram: Up to 3 years
|
as evaluated per the RECIST v1.1 criteria.
|
Up to 3 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
anti-drog antikropp (ADA)
Tidsram: Upp till 3 år
|
Förekomst och karakterisering av anti-läkemedelsantikropp (ADA).
|
Upp till 3 år
|
|
area under the curve (AUC)
Tidsram: Up to 3 years
|
area under the curve (AUC) of single and multiple doses of IBI3005
|
Up to 3 years
|
|
maximum concentration (Cmax)
Tidsram: Up to 3 years
|
maximum concentration (Cmax) of single and multiple doses of IBI3005
|
Up to 3 years
|
|
time to maximum concentration (Tmax)
Tidsram: Up to 3 years
|
time to maximum concentration (Tmax) of single and multiple doses of IBI3005
|
Up to 3 years
|
|
clearance (CL)
Tidsram: Up to 3 years
|
clearance (CL) of single and multiple doses of IBI3005
|
Up to 3 years
|
|
apparent volume of distribution (V)
Tidsram: Up to 3 years
|
apparent volume of distribution (V) of single and multiple doses of IBI3005
|
Up to 3 years
|
|
half-life (t1/2)
Tidsram: Up to 3 years
|
half-life (t1/2) of IBI3005 to the last administration of IBI3005
|
Up to 3 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CIBI3005A102
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .